<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Hudson, Marie</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Results of the International Scleroderma Renal Crisis Survey</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2012</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2012-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">9-9</style></pages><abstract><style  face="normal" font="default" size="100%">Data from a prospective study showed results consistent with some, but not all, prior studies [Penn H and Denton CP. Curr Opin Rheumatol 2008; Guillevin L et al. Rheumatology 2012]. Compared with retrospective data, the findings suggested worse outcomes with exposure to angiotensin converting enzyme inhibitors prior to the onset of scleroderma renal crisis.</style></abstract><number><style face="normal" font="default" size="100%">19</style></number><volume><style face="normal" font="default" size="100%">12</style></volume></record></records></xml>